Fig. 4

Lovastatin did not improve spatial and temporal gait parameters in Ube3a^−/+ mice. Several metrics of gait were assessed in Ube3a^−/+ mice (AS) treated with lovastatin. Lovastatin at any dose did not have any effect on either (A) forelimb stance width or (D) hindlimb stance width in Ube3a^−/+ mice. However, when treated with lovastatin, reductions in forelimb stride length were observed at 10 mg/kg or 100 mg/kg (B) and in the (E) hindlimb stride length at 10 mg/kg. Similarly, a dose of either 10 mg/kg or 100 mg/kg altered both the (C) forelimb stride frequency and (F) hindlimb stride frequency, exhibiting values closer to vehicle treated Ube3a^+/+ mice (WT). (G) Reductions in forelimb stride duration were observed when treated with either 10 mg/kg or 100 mg/kg of lovastatin. (J) Hindlimb stride duration was also reduced to levels closer to Ube3a^+/+ mice when treated with 10 mg/kg of lovastatin. Although no changes were seen at any dose in (H) forelimb propulsion duration, Ube3a^−/+ animals treated with either 10 mg/kg or 100 mg/kg displayed reductions in (K) hindlimb propulsion duration. Finally, (I) forelimb stance duration was reduced when Ube3a^−/+ mice were treated either 10 mg/kg or 100 mg/kg of lovastatin, and (L) hindlimb stance duration was reduced at each dose of lovastatin evaluated. Number of mice tested for gait: WT Veh N = 10, 10 mg/kg N = 8, 30 mg/kg N = 8, 100 mg/kg N = 7; AS Veh N = 9, 10 mg/kg N = 10, 30 mg/kg N = 9, 100 mg/kg N = 10. * p < 0.05, two-way ANOVA, one–way ANOVA followed by Dunnett’s post hoc analysis